|
Group
|
Cell cycle distribution (%)
|
|---|
|
G0/G1
|
S
|
G2/M
|
|---|
|
H1975 cells
| | | |
|
Control
|
61.5 + 3.6
|
29.4 + 2.3
|
9.1 + 6.3
|
|
BKM120 + MEK162
|
81.3 + 2.7*
|
12.9 + 6.5
|
5.8 + 2.2
|
|
BIBW2992 + ARQ197
|
92.6 + 5.5*#
|
3.5 + 2.4
|
3.9 + 1.4
|
|
H460 cells
| | | |
|
Control
|
58.4 + 6.6
|
24.4 + 8.3
|
17.2 + 7.3
|
|
BKM120 + MEK162
|
90.5 + 3.8*▲
|
6.1 + 5.2
|
3.4 + 3.2
|
|
BIBW2992 + ARQ197
|
59.5 + 5.6#▲
|
22.7 + 3.4
|
17.8 + 7.4
|
|
A549 cells
| | | |
|
Control
|
63.1 + 9.1
|
25.7 + 6.3
|
11.2 + 4.3
|
|
BKM120 + MEK162
|
85.3 + 7.6*&
|
8.8 + 2.5
|
5.9 + 3.8
|
|
BIBW2992 + ARQ197
|
61.4 + 5.5#▲
|
27.1 + 6.4
|
11.5 + 6.4
|
- H1975, H460, and A549 cells were treated with 1 μM MEK162/5 μM BKM120 combination and 1 µM BIBW2992 (EGFR inhibitor)/2 µM ARQ 197 (MET inhibitor) combination for 48 h. Control cells were treated with 0.05% DMSO. Each value represents mean ± SD obtained from three independent experiments
- *P < 0.05 vs. Control; #P < 0.05 vs. BKM120 + MEK162; ▲P < 0.05 vs. H1975 cells; &P < 0.05 vs. H460 cells under the same cell cycle phase and the same drug treatment
